Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD).
- DOI
- 10.1016/j.cpt.2025.12.001
- Published
- 2026 May
- Container
- Cancer pathogenesis and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.cpt.2025.12.001,
title = {Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD).},
author = {Qian K and Xing S and Wei Y and Wang L and Yang J and Li F and Gu Z and Wang N and Dou L and Liu D},
year = {2026},
journal = {Cancer pathogenesis and therapy},
doi = {10.1016/j.cpt.2025.12.001},
url = {https://doi.org/10.1016/j.cpt.2025.12.001}
}RIS
TY - JOUR TI - Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD). AU - Qian K AU - Xing S AU - Wei Y AU - Wang L AU - Yang J AU - Li F AU - Gu Z AU - Wang N AU - Dou L AU - Liu D PY - 2026 JO - Cancer pathogenesis and therapy DO - 10.1016/j.cpt.2025.12.001 UR - https://doi.org/10.1016/j.cpt.2025.12.001 ER -
APA
K, Q., S, X., Y, W., L, W., J, Y., F, L., Z, G., N, W., L, D., & D, L. (2026). Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD).. Cancer pathogenesis and therapy. https://doi.org/10.1016/j.cpt.2025.12.001
Source records
- pubmed · retrieved 2026-09-25T19:13:26.968Z